[Crossref] [PubMed] Krajnc N, Itariu B, Macher S, et al
Ongoing randomized trials the gold standard for evaluating new uses of drugs are looking at the effects of GLP-1 drugs in early Alzheimers disease, with results expected later in 2025
The reality is that obesity and weight gain are not just matters of willpowerthey are complex medical conditions influenced by genetics, hormones, and metabolic adaptation
Alcohol particularly affects the liver antioxidant, Glutathione, leading to mitochondrial damage and cell death due to unimpeded lipid peroxidation [2]
Beyond education, pharmacists contribute to closely monitoring treatment efficacy and safety by assessing key metrics such as HbA1c levels, weight changes, and cardiovascular markers (Miller et al
Semaglutide started out as a diabetes medication, but its now FDA-approved for weight loss too